Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is randomized, multicentre study aimed to compare a standard maintenance therapy with Interferon-Dexamethasone with an experimental therapy based on Thalidomide-Dexamethasone in patients with multiple myeloma who responded to ThaDD induction therapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Università Politecnica delle Marche
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Interferon-alpha; Interferons; Liposomal doxorubicin; Thalidomide

Criteria

Inclusion Criteria:

• patients with newly diagnosed or advanced multiple myeloma achieving at least a minimal response after induction with ThaDD regimen

• Written consent

Exclusion Criteria:

• peripheral neuropathy >= grade 2

• neutropenia < 1000/mcl or thrombocytopenia < 50000/mcl

• severe depression

• organ disfunction > grade 2